Antimicrobial susceptibility testing in biofilm-growing bacteria  by Macia, M.D. et al.
Antimicrobial susceptibility testing in bioﬁlm-growing bacteria
M. D. Macia, E. Rojo-Molinero and A. Oliver
Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigacion Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain
Abstract
Bioﬁlms are organized bacterial communities embedded in an extracellular polymeric matrix attached to living or abiotic surfaces. The
development of bioﬁlms is currently recognized as one of the most relevant drivers of persistent infections. Among them, chronic
respiratory infection by Pseudomonas aeruginosa in cystic ﬁbrosis patients is probably the most intensively studied. The lack of correlation
between conventional susceptibility test results and therapeutic success in chronic infections is probably a consequence of the use of
planktonically growing instead of bioﬁlm-growing bacteria. Therefore, several in vitro models to evaluate antimicrobial activity on bioﬁlms
have been implemented over the last decade. Microtitre plate-based assays, the Calgary device, substratum suspending reactors and the
ﬂow cell system are some of the most used in vitro bioﬁlm models for susceptibility studies. Likewise, new pharmacodynamic parameters,
including minimal bioﬁlm inhibitory concentration, minimal bioﬁlm-eradication concentration, bioﬁlm bactericidal concentration, and
bioﬁlm-prevention concentration, have been deﬁned in recent years to quantify antibiotic activity in bioﬁlms. Using these parameters,
several studies have shown very signiﬁcant quantitative and qualitative differences for the effects of most antibiotics when acting on
planktonic or bioﬁlm bacteria. Nevertheless, standardization of the procedures, parameters and breakpoints, by ofﬁcial agencies, is needed
before they are implemented in clinical microbiology laboratories for routine susceptibility testing. Research efforts should also be directed
to obtaining a deeper understanding of bioﬁlm resistance mechanisms, the evaluation of optimal pharmacokinetic/pharmacodynamic models
for bioﬁlm growth, and correlation with clinical outcome.
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Introduction
The development of bioﬁlms is currently recognized as one of
the most relevant drivers of persistent infections, and consti-
tutes a major challenge for clinical microbiologists and
clinicians [1]. The aims of this review are to describe the
methods for antimicrobial susceptibility testing of bioﬁlms, and
to analyse the pharmacodynamic parameters obtained from
these studies, in order to discuss their application in the clinical
microbiology laboratory as a tool to guide therapeutic
strategies.
Bioﬁlms are deﬁned as organized bacterial communities
embedded in an extracellular polymeric matrix attached to
living or abiotic surfaces. This social behaviour arises as an
adaptation strategy for survival in hostile environments,
including the human host [2].
The ﬁrst stage of bioﬁlm formation is adherence to a
surface, helped by ﬂagella and pili in Gram-negative bacteria
[3,4] or surface proteins in Gram-positive bacteria [5]. After
attachment, the bioﬁlm proliferates and produces extracellular
matrix, composed mainly of exopolysaccharides, and small
amounts of protein, DNA, bacterial lytic products, and
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compounds from the host [6,7]. Finally, a dispersal stage
occurs, where some bacteria are released from the bioﬁlm
matrix to colonize new surfaces to start the cycle again [8].
Bioﬁlm genesis requires cell–cell signalling for the differen-
tiation of bacteria into complex communities. Quorum sensing
regulates cell density, inducing changes in bacterial gene
transcription, depending on the concentration of diffusible
signal molecules such as second messengers, signalling mole-
cules, and small RNAs [3].
Role of Bioﬁlms in Infectious Diseases
According to the available information [8], up to 65–80% of all
infections are associated with bioﬁlm formation, highlighting
their enormous clinical impact. Bioﬁlms are typically implicated
in chronic infections, in contrast to the planktonic bacteria
involved in acute processes [1,9–11]. Chronic infections are
characterized by the persistence of the aetiological agent,
despite (in principle) adequate antibiotic therapy and host
immune responses. Such types of infection have been found in
almost all tissues of the human body, especially affecting
patients with chronic wound infections and patients with
chronic lung infections such as cystic ﬁbrosis (CF) [12]. Bioﬁlms
are involved in >60% of chronic wound infections. The wounds
may be colonized by one type of microorganism or, more
frequently, by several species [13], the most common bacteria
being Staphylococcus aureus and Pseudomonas aeruginosa [14,15].
Chronic respiratory infection by P. aeruginosa is the main
cause of morbidity and mortality in CF patients, and nearly 80%
of CF patients are at risk of developing it [16]. In CF, as well as
in other chronic lung diseases such as bronchiectasis and
chronic obstructive pulmonary disease [17,18], the bioﬁlm
mode of growth, together with the remarkable intrinsic
antibiotic resistance of P. aeruginosa and the high prevalence
of hypermutable strains [19,20], make eradication of chronic
infection practically impossible.
P. aeruginosa also has an important role in ventilator-asso-
ciated pneumonia development, which occurs in an approxi-
mately in one-third of intubated patients, and has been
associated with bioﬁlm formation in endotracheal tubes [21].
Bioﬁlm-related infections have also been described on a
wide range of biomedical devices, including prostheses,
catheters, tracheal tubes, and cardiac valves [22–26]. The
development of infection depends on the type and the length
of use of the implant. In some cases, the attachment of bacteria
to indwelling devices is favoured by host ﬁbronectin and
ﬁbrinogen [27]. On the other hand, bioﬁlms formed on this
kind of surfaces may seed bacteria into the bloodstream,
causing secondary infections.
Antimicrobial Resistance in Bioﬁlms
One of the most important characteristic of bioﬁlms is their
increased tolerance to antimicrobial agents [28]. It has been
proved that bioﬁlms can tolerate up to 100–1000 times higher
concentrations of antibiotics and disinfectants than planktonic
cells [1,9,29–32]. Some of the several mechanisms that have
been proposed over the years to contribute to bioﬁlm
phenotypic resistance are detailed below.
Decrease in antibiotic penetration
The exopolysaccharide matrix and bioﬁlm structure reduce
diffusion and act as a primary barrier, preventing the entrance
of polar and charged antibiotics [33]. Alginate and extracellular
DNA, which are components of the extracellular matrix, have
shown antibiotic-chelating activity [34].
Different growth rates and nutrient gradients within the
bioﬁlm
Bioﬁlms contain channels that allow the circulation of water,
nutrients, and oxygen [35]. However, during bioﬁlm formation,
a gradient of available substances is established: the outer layers
become aerobic and metabolically active, and the inner layers
become anaerobic and nutrient-deﬁcient, with a reduced
growth rate [3,36–39]. Some antibiotics, such as ﬂuoroquinol-
ones, b-lactams, and aminoglycosides, are not active in
anaerobic conditions; consequently, they affect only the outer
part of the bioﬁlm, where oxygen is present [40,41]. Addition-
ally, most antibiotics show more effective killing of rapidly
dividing cells, so slow growth contributes to tolerance [1,42].
Persister phenomenon
Persisters have been described as dormant variants arising
within bacterial bioﬁlms that are characteristically highly
tolerant to antibiotics [43]. Whereas planktonic persisters
are cleared by the host immune response, bioﬁlm persisters
are shielded from host defence [42], and may cause a relapse
of infection.
Induction of resistance mechanisms
This type of resistance depends on the presence of antibiotic,
and can be speciﬁc or non-speciﬁc for a particular antimicro-
bial. One of the most universal non-speciﬁc mechanism is the
upregulation of efﬂux pumps. Indeed, various studies have
revealed differential expression of several conventional and
bioﬁlm-speciﬁc antibiotic resistance genes in bioﬁlms as
compared with planktonic growth [44]. Moreover, the
phenotypes produced by speciﬁc resistance mechanisms can
signiﬁcantly differ between bioﬁlm and planktonic growth [45].
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Mutational resistance
Although most of the hypotheses are based on bioﬁlm
physiological characteristics, classic mutational mechanisms
play a major role in bioﬁlm antibiotic resistance [46]. Actually,
the increased antibiotic tolerance driven by the special bioﬁlm
physiology and architecture may favour gradual mutational
resistance development during antimicrobial treatment, this
being particularly favoured in mutator strains, which are highly
prevalent in chronic respiratory infections [19,46,47]. In fact,
recent ﬁndings have shown that mutagenesis is intrinsically
increased in bioﬁlms and that hypermutation plays an impor-
tant role in development, adaptation and diversiﬁcation
processes [48–51].
Gene transfer
The bioﬁlm structure allows effective horizontal gene transfer
between bacteria, which plays an important role in the
development of resistance to antibiotics [52].
In vitro Bioﬁlm Models
Owing to the increasing interest in antimicrobial susceptibil-
ity testing in bioﬁlms, several methods have been imple-
mented in the last few years. Depending on nutrient
delivery, bioﬁlm growth models may be classiﬁed as closed
systems (batch culture) and open systems (continuous
culture) [53]. Closed models have the advantage of simplicity
and applicability in high-throughput analysis, whereas open
models allow better control of growth parameters and
dynamics [54]. To choose the optimal experimental
approach, it is necessary to consider which one is better
suited for the assay to be performed. The most relevant
systems are described below.
Closed systems
Microtitre plate method. The microtitre plate (e.g. 96-well plate)
ﬁlled with sterile broth culture (depending on the type of
microorganism) is inoculated with bacteria, and incubated for
24–48 h with an appropriate atmosphere and temperature.
Bioﬁlm formation takes place as a ring around the well. After
rinsing of wells to remove planktonic cells, the bioﬁlm can be
stained with crystal violet and dissolved in acetone–ethanol for
quantiﬁcation of the biomass by measuring the optical density
(OD) [55]. The main advantages are the ease, rapidity and
reproducibility of the method. Conversely, one of the main
disadvantages is the absence of a relationship between biomass
and bioﬁlm viability, as crystal violet stains dead and viable cells
equally [56].
Calgary bioﬁlm device. This device is a disposable 96-well
microtitre plate with a lid that incorporates the same number
of removable polystyrene pegs [57]. The bacteria are inocu-
lated in the microtitre wells with broth culture, and the plate is
incubated with or without [58] shaking to allow cells to attach
to pegs. The bioﬁlm is formed around the pegs, while
planktonic bacteria remain in the broth. To facilitate the
growth of bacteria, the pegs can be coated with a substance,
such as L-lysine or hydroxyapatite. One of the disadvantages of
this method is the possibility of contamination resulting from
manipulation when pegs are removed for further analysis.
Open systems
Open systems try to replicate the in vivo conditions through
the control of nutrient delivery, ﬂow, and temperature.
Moreover, these systems make possible the implementation
of pharmacokinetic/pharmacodynamic (PK/PD) models, as well
as allowing observation by microscopy. Another advantage is
the study of bioﬁlm dynamics in the absence of planktonic cells
(eliminated by ﬂow).
Flow cell. The ﬂow cell system has been demonstrated to be
the best approach for modelling bioﬁlm formation, as real-time
non-destructive confocal laser scanning microscopy (CLSM)
analyses can be performed [59]. The system includes a vessel
with sterile broth culture that provides medium through a
multichannel peristaltic pump. The bacteria are directly
inoculated into the ﬂow cells by injection through silicone
tubing. Cells are attached to a surface, where bioﬁlm starts to
develop. The most common attachment surfaces used are
transparent and non-ﬂuorescent microscope coverslips, in
order to allow bioﬁlm evolution to be observed. Another
advantage is that a deﬁned constant environment is provided
by laminar ﬂow [60]. In addition, bioﬁlms formed in this model
are thicker than those obtained with the Calgary bioﬁlm device
and the CDC Bioﬁlm Reactor. Despite the many advantages,
the process takes several days to prepare and is very
time-consuming. Moreover, the coverslips are very fragile
and can break easily [61]. Fig. 1 summarizes antimicrobial
susceptibility testing with the ﬂow cell bioﬁlm model.
Suspended substratum reactor. CDC Bioﬁlm Reactor. This system
consists of a glass reactor connected to a ﬂask with sterile
broth culture, which is pumped through the system. Eight
coupon holders, each one housing three coupons (diameter,
12.7 mm; surface area, 2.53 cm2), are suspended from a lid
placed into the reactor ﬁlled with growth medium. The
bacteria are inoculated into the reactor, and the bioﬁlm is
formed upon coupons while the broth is mixed with a stirring
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vane by magnetic rotation. Owing to the rotation, the bioﬁlm
grows under high-shear conditions. Coupons can be sampled
by removing individual coupon holders and replacing them in
the lid to continue the experiment in aseptic conditions. These
coupons can be made from a large number of materials
(polycarbonate, mild steel, stainless steel, PVC, vinyl, glass,
etc.), according to the microorganism and assay. The condi-
tions of the experiments can be controlled by modifying the
ﬂow speed, temperature, and residence times. This method
allows the study of seeding planktonic cells by sampling the
bulk ﬂuid phase.
Application of Bioﬁlm Models to
Antimicrobial Susceptibility Testing
Classic antibiotic susceptibility tests (from disk diffusion to
automatic broth microdilution methods) that provide the
MIC used to deﬁne the susceptibility breakpoints and the PK/
PD parameters that predict therapeutic success are per-
formed with planktonically growing bacteria. As described
before, bioﬁlm-growing microorganisms are signiﬁcantly more
resistant to antibiotics than those growing planktonically, and
the corresponding breakpoints have not been established
[62]. Therefore, the results of classic susceptibility tests
cannot be used to predict therapeutic success for bioﬁlm
infections, and offer no guidelines for clinicians to treat such
infections. Thus, there is growing interest in the development
of susceptibility tests speciﬁc for bioﬁlm-growing bacteria. As
summarized in Table 1, several in vitro bioﬁlm models have
been implemented and tested in a number of different
bacterial species. Nevertheless, the current lack of standard-
ization of the methods, parameters and interpretation of
results limits the application of the obtained data to the
clinical setting, including the comparison of different treat-
ment strategies.
Susceptibility assay on microtitre plates
In this simple quantitative assay, wells containing sterile growth
medium are inoculated with bacteria and allowed to grow. The
capacity of antibiotics to prevent or eliminate bioﬁlms can be
measured by adding various concentrations of test compounds
to nascent or mature bioﬁlms. Quantiﬁcation of bioﬁlm
production is achieved, following removal of spent culture
ﬂuid from the wells and an optional wash in buffer to remove
‘loosely adherent cells’, by staining for crystal violet, which is a
(a) (b) (c)
FIG. 1. Antimicrobial susceptibility testing with the ﬂow cell bioﬁlm model. (1) Medium bottle, where antibiotics are added and circulate through
the ﬂow cell for the required time. (2) Peristaltic pump, which provides laminar ﬂow. (3) Bubble traps, which avoid destructive air bubbles forming on
the ﬂow cells. (4) Flow cells, where the bioﬁlm develops. (5) Waste bottle. (a) Typical mushroom structure of Pseudomonas aeruginosa bioﬁlm tagged
with green ﬂuorescent protein (GFP). (b) Red propidium iodide staining of dead cells/areas to observe and quantify the bactericidal effect during
antibiotic treatment of GFP-tagged P. aeruginosa bioﬁlm. (c) Different structural distribution of a mixed bioﬁlm of two P. aeruginosa strains tagged
with enhanced yellow ﬂuorescent protein (outer part) and enhanced cyan ﬂuorescent protein (internal part).
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 981–990
984 Clinical Microbiology and Infection, Volume 20 Number 10, October 2014 CMI
T
A
B
L
E
1
.
O
v
e
rv
ie
w
o
f
th
e
in
vi
tr
o
b
io
ﬁ
lm
m
o
d
e
ls
m
o
st
c
o
m
m
o
n
ly
u
se
d
fo
r
a
n
ti
m
ic
ro
b
ia
l
su
sc
e
p
ti
b
il
it
y
te
st
in
g
B
io
ﬁ
lm
m
o
d
e
l
P
a
ra
m
e
te
rs
M
ic
ro
ti
tr
e
p
la
te
s
[6
3
]
C
a
lg
a
ry
d
e
v
ic
e
[5
7
,6
4
]
F
lo
w
c
e
ll
m
o
d
e
l
[5
9
,6
0
,6
5
]
S
u
sp
e
n
d
e
d
su
b
st
ra
tu
m
re
a
c
to
r
[6
6
]
N
u
tr
ie
n
t
av
ai
la
b
ili
ty
a
C
lo
se
d
sy
st
e
m
(s
ta
ti
c)
C
lo
se
d
sy
st
e
m
(s
ta
ti
c)
O
p
e
n
sy
st
e
m
(d
yn
am
ic
)
O
p
e
n
sy
st
e
m
(d
yn
am
ic
)
B
io
ﬁ
lm
fo
rm
at
io
n
A
d
h
e
re
n
ce
to
th
e
w
e
lls
(p
o
ly
st
yr
e
n
e
,
p
o
ly
p
ro
p
yl
e
n
e,
o
r
p
o
ly
ca
rb
o
n
at
e
)
A
d
h
e
re
n
ce
to
p
e
g
lid
s
(p
o
ly
st
yr
e
n
e
,
p
o
ly
p
ro
p
yl
e
n
e,
o
r
p
o
ly
ca
rb
o
n
at
e
)
A
d
h
e
re
n
ce
to
gl
as
s
su
rf
ac
e
o
f
co
ve
rs
lip
A
d
h
e
re
n
ce
to
co
u
p
o
n
s
(p
o
ly
ca
rb
o
n
at
e
,
si
lic
o
n
e
,
st
ai
n
le
ss
st
e
e
l,
e
tc
.)
A
n
ti
b
io
ti
c
st
u
d
y
W
e
lls
in
cu
b
at
e
d
w
it
h
an
ti
b
io
ti
c(
s)
D
ai
ly
ri
n
si
n
g
an
d
m
e
d
iu
m
re
n
e
w
al
B
io
ﬁ
lm
s
o
n
p
e
gs
in
cu
b
at
e
d
w
it
h
an
ti
b
io
ti
c(
s)
D
ai
ly
ri
n
si
n
g
an
d
m
e
d
iu
m
re
n
e
w
al
A
n
ti
b
io
ti
cs
ar
e
ad
d
e
d
to
th
e
m
e
d
iu
m
b
o
tt
le
an
d
ci
rc
u
la
te
d
th
ro
u
gh
th
e
ﬂ
o
w
ce
ll
fo
r
th
e
re
q
u
ir
e
d
ti
m
e
A
n
ti
b
io
ti
cs
ar
e
ad
d
e
d
to
th
e
b
u
lk
ﬂ
u
id
p
h
as
e
,
si
m
u
lt
an
e
o
u
sl
y
e
x
p
o
si
n
g
al
l
co
u
p
o
n
s
B
io
m
as
s/
C
FU
co
u
n
t
C
V
st
ai
n
E
th
an
o
l
d
is
so
lu
ti
o
n
O
D
5
7
0
n
m
m
e
as
u
re
m
e
n
t
(m
ic
ro
ti
tr
e
p
la
te
re
ad
e
r)
B
io
ﬁ
lm
tr
an
sf
e
re
n
ce
b
y
ce
n
tr
ifu
ga
ti
o
n
o
r
so
n
ic
at
io
n
O
D
6
5
0
n
m
m
e
as
u
re
m
e
n
t
(0
-6
h
at
3
7
°C
)
Se
ri
al
te
n
-f
o
ld
d
ilu
ti
o
n
s
p
la
te
d
B
io
ﬁ
lm
d
e
ta
ch
m
e
n
t
an
d
co
lle
ct
io
n
b
y
w
as
h
in
g
th
e
ﬂ
o
w
ce
ll
ch
an
n
e
ls
w
it
h
gl
as
s
b
e
ad
s
in
sa
lin
e
Se
ri
al
te
n
-f
o
ld
d
ilu
ti
o
n
s
p
la
te
d
B
io
ﬁ
lm
tr
an
sf
e
re
n
ce
b
y
so
n
ic
at
io
n
an
d
vi
go
ro
u
s
vo
rt
e
x
in
g
Se
ri
al
te
n
-f
o
ld
d
ilu
ti
o
n
s
p
la
te
d
M
ic
ro
sc
o
p
ic
an
al
ys
is
Im
ag
in
g
to
d
et
e
rm
in
e
vi
ab
ili
ty
(l
iv
e
/
d
e
ad
ce
ll
ra
ti
o
)
SE
M
C
L
SM
B
o
th
re
q
u
ir
e
ﬁ
x
at
io
n
an
d
st
ai
n
in
g,
w
h
ic
h
ar
e
d
e
st
ru
ct
iv
e
te
ch
n
iq
u
e
s
fo
r
b
io
ﬁ
lm
s
C
L
SM
B
ac
te
ri
a
ar
e
p
re
vi
o
u
sl
y
ta
gg
e
d
w
it
h
FP
SE
M
C
L
SM
St
ai
n
in
g
is
n
e
e
d
e
d
St
ru
ct
u
ra
l
an
al
ys
is
N
o
t
d
e
sc
ri
b
e
d
3
D
im
ag
in
g
an
d
vi
ab
ili
ty
st
u
d
ie
s
(l
iv
e
/d
e
ad
ce
ll
ra
ti
o
)
[6
7
]
A
n
al
ys
is
o
f
st
ru
ct
u
ra
l
p
ar
am
e
te
rs
(b
io
m
as
s,
th
ic
k
n
e
ss
,
ro
u
gh
n
e
ss
co
e
fﬁ
ci
e
n
t,
e
tc
.)
w
it
h
C
o
m
st
at
so
ft
w
ar
e
3
D
im
ag
in
g
an
d
vi
ab
ili
ty
st
u
d
ie
s
(l
iv
e
/d
e
ad
ce
ll
ra
ti
o
)
[6
8
]
R
e
le
va
n
t
ch
ar
ac
te
ri
st
ic
s
Fe
as
ib
le
an
d
re
p
ro
d
u
ci
b
le
M
in
im
iz
e
s
co
n
ta
m
in
at
io
n
ri
sk
B
io
ﬁ
lm
th
ic
k
n
e
ss
o
f
<
5
0
lm
Fe
as
ib
le
an
d
re
p
ro
d
u
ci
b
le
M
in
im
iz
e
s
co
n
ta
m
in
at
io
n
ri
sk
B
io
ﬁ
lm
th
ic
k
n
e
ss
o
f
<
5
0
lm
D
ir
e
ct
re
al
-t
im
e
n
o
n
-d
es
tr
u
ct
iv
e
vi
su
al
iz
at
io
n
an
d
fo
llo
w
-u
p
o
f
b
io
ﬁ
lm
s
o
ve
r
ti
m
e
B
io
ﬁ
lm
th
ic
k
n
e
ss
o
f
>
5
0
lm
A
llo
w
s
si
m
u
lt
an
e
o
u
s
an
al
ys
is
o
f
sh
e
d
d
in
g
p
la
n
k
to
n
ic
ce
lls
an
d
b
io
ﬁ
lm
-e
m
b
e
d
d
e
d
ce
lls
M
ic
ro
o
rg
an
is
m
s
te
st
e
d
St
ap
hy
lo
co
cc
us
au
re
us
[6
9
]
C
an
di
da
al
bi
ca
ns
[7
0
]
Ps
eu
do
m
on
as
ae
ru
gi
no
sa
[7
1
]
St
re
p
to
co
cc
us
p
ne
um
on
ia
e
[7
2
]
Li
st
er
ia
m
on
oc
yt
og
en
es
[7
3
]
Ps
eu
do
m
on
as
ae
ru
gi
no
sa
[5
8
]
St
ap
hy
lo
co
cc
us
sp
p
.
[5
7
]
St
re
p
to
co
cc
us
sp
p
.
[7
4
]
M
yc
ob
ac
te
ri
um
sp
p
.
[7
5
]
C
an
di
da
sp
p
.
[7
6
]
B
ur
kh
ol
de
ri
a
sp
p
.
[7
7
]
Ps
eu
do
m
on
as
ae
ru
gi
no
sa
[4
6
]
St
ap
hy
lo
co
cc
us
sp
p
.
[7
8
]
Ps
eu
do
m
on
as
ae
ru
gi
no
sa
[6
6
]
C
an
di
da
sp
p
.
[7
9
]
St
ap
hy
lo
co
cc
us
sp
p
.
[8
0
,8
1
]
C
L
SM
,
co
n
fo
ca
l
la
se
r
sc
an
n
in
g
m
ic
ro
sc
o
p
y;
C
V
,
cr
ys
ta
l
vi
o
le
t;
FP
,
ﬂ
u
o
re
sc
e
n
t
p
ro
te
in
;
O
D
,
o
p
ti
ca
l
d
en
si
ty
;
SE
M
,
sc
an
n
in
g
e
le
ct
ro
n
m
ic
ro
sc
o
p
y.
a C
lo
se
d
sy
st
e
m
:
b
at
ch
cu
lt
u
re
.
O
p
e
n
sy
st
e
m
:
co
n
ti
n
u
o
u
s
cu
lt
u
re
.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 981–990
CMI Macia et al. Susceptibility assay in bioﬁlm 985
cationic dye that non-speciﬁcally stains negatively charged
bioﬁlm constituents via ionic interactions [55]. Protocols may
also be modiﬁed to incorporate different stains. The crystal
violet is then dissolved by the addition of a standard volume of
ethanol (or glacial acetic acid), and the absorbance is measured
at 570 nm with a microplate spectrophotometer. Bacterial
viability within the bioﬁlm can be determined by use of the blue
phenoxazin dye resazurin, which is reduced by viable bacteria
to the pink, ﬂuorescent compound resoruﬁn [82,83]. After
removal of the medium and washing of the wells with
phosphate-buffered saline, bioﬁlms are incubated with resazu-
rin at room temperature in the dark, and ﬂuorescence is then
measured at a wavelength of 590 nm, with an excitation
wavelength of 550 nm.
Susceptibility assay on the Calgary bioﬁlm device
The bioﬁlms are grown on pegs suspended from the lid of a
microtitre plate by incubation at 37°C for 20 h with either
rocking at 20 Hz or no movement [57]. The peg lids are then
rinsed and placed onto ﬂat-bottomed microtitre plates, where
they are incubated (normally, 18–20 h at 37°C) in the
presence of different concentrations of the antibiotics. After
antibiotic exposure, the peg lids are again rinsed, and placed
into antibiotic-free medium in a ﬂat-bottomed microtitre plate
(bioﬁlm recovery plate). Light centrifugation (e.g. 805 g for
20 min) or 5 min of sonication at room temperature are used
to transfer bioﬁlms from pegs to wells. The OD650 nm is then
measured with a microtitre plate colorimeter before and after
incubation at 37°C for 6 h. Adequate bioﬁlm growth for the
positive control wells is deﬁned as a mean OD650 nm difference
(OD650 nm at 6 h minus OD650 nm at 0 h) of ≥0.05. The bioﬁlm
inhibitory concentrations are deﬁned as the lowest concen-
trations of drug that result in an OD650 nm difference of ≤10%
of the mean of two positive control well readings [64]. The
10% cut-off represents a 1 log difference in growth after 6 h of
incubation. This system allows incubation with antibiotics at
different time-points, with daily rinsing and antibiotic renewal
[64]. Modiﬁcations of this assay have also allowed determina-
tion of the number of viable cells and antibiotic-resistant
mutants by simply plating serial ten-fold dilutions on medium
and medium plus proper antibiotic concentrations, respec-
tively, of the transferred bioﬁlms [58]. The bioﬁlm structure
can be studied with scanning electron microscopy or CLSM
after removal of the pegs [67]. Before microscopic observa-
tion, the bioﬁlm has to be ﬁxed to the surfaces of the pegs.
Some of the available ﬁxing techniques are destructive to
bioﬁlm, and only permit observation of the structure of
underlying bacteria or observation of the extracellular poly-
meric matrix. For the use of CLSM, it is necessary to stain the
bioﬁlm with appropriated ﬂuorophores.
Susceptibility assay on the ﬂow cell model
Nascent or mature bioﬁlms are challenged with antibiotics by
adding these to the medium. Daily antibiotic renewal through-
out the experiment is advisable. Confocal images acquired
section by section generate useful three-dimensional images of
bioﬁlm communities after image processing [84] to visualize
and monitor the effect of the antibiotic. For CLSM, bacteria
can be ﬂuorescently tagged with, for instance, green ﬂuores-
cent protein, cyan ﬂuorescent protein, or yellow ﬂuorescent
protein, as previously described [59]. Dead cells/areas may be
stained red with propidium iodide to observe and quantify the
bactericidal effect [85]. Structural parameters such as biomass,
average and maximum thickness and roughness coefﬁcient can
be measured from a signiﬁcant number of images (at least four
pictures per channel per ﬂow cell) by analysis with Comstat
software [86]. Viable cells and antibiotic-resistant mutants can
also be determined by washing the ﬂow cell channels with a
1-mL glass bead suspension in 0.9% NaCl to detach and collect
bioﬁlms at the end of the experiments, and then plating serial
ten-fold dilutions on medium and medium plus proper
antibiotic concentrations, respectively [46].
Susceptibility assay on the CDC Bioﬁlm Reactor
Bioﬁlms develop on coupons suspended from the lid and
immersed in growth medium. Antimicrobial agents can be
added to the bulk ﬂuid phase, simultaneously exposing all
coupons. Sampling is achieved by removing coupon holders
from the lid at various times during the experimental run.
Coupons are placed in tubes with normal saline, sonicated for
5 min, and then vigorously vortexed for 60 s (three cycles) to
dislodge and disperse the cells from the bioﬁlm, to be used for
plate counting and epiﬂuorescence microscopy [87]. The
bioﬁlm structure can be observed by CLSM with staining of
coupons [68,87].
Parameters of Antibiotic Activity on Bioﬁlms
The pharmacodynamic parameters used to quantify antimicro-
bial activity in planktonic and bioﬁlm-growing bacteria are
summarized in Table 2. Similarly to the conventional MIC, the
minimal bioﬁlm inhibitory concentration (MBIC) was ﬁrst
deﬁned, by Moskowitz et al., using the Calgary device [64], as
the lowest concentration of drug that resulted in an OD650 nm
difference of ≤10% of the mean of two positive control well
readings. Regarding cell counts, the MBIC is the lowest
concentration of an antimicrobial at which there is no
time-dependent increase in the mean number of bioﬁlm viable
cells when an early exposure time is compared with a later
exposure time. Likewise, the planktonic minimal bactericidal
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concentration (MBC), the bioﬁlm bactericidal concentration
(BBC), deﬁned as the lowest concentration that killed 99.9% of
the cells recovered from a bioﬁlm culture compared to growth
control, has also been used to evaluate the efﬁcacy of
antibiotics on bioﬁlm-growing bacteria [88,89]. Another
parameter that is used is the minimal bioﬁlm-eradication
concentration (MBEC), deﬁned as the lowest concentration of
antibiotic required to eradicate the bioﬁlm [57] or, in other
words, the lowest concentration of antimicrobial agent that
prevents visible growth in the recovery medium used to
collect bioﬁlm cells (0 CFU/peg on plate counts).
All of these parameters explore the activity of antibiotics on
mature bioﬁlms, which means that the bioﬁlm has been
established; however, in the case of CF patients, for instance,
the early stage of colonization is when P. aeruginosa can be
effectively eradicated with appropriate antibiotic therapy. In this
sense, the bioﬁlm-prevention concentration (BPC) is an inter-
esting parameter that could be used with the aim of reducing the
cell density to prevent bioﬁlm formation. BPC determination
involves a modiﬁcation of the MBIC assay, consisting of
incubating peg lids with the planktonic inoculum at the time of
exposure to different antibiotic concentrations [89].
Interpretation and Application of
Susceptibility Studies in Bioﬁlms
Table 3 summarizes the available data comparing the pharma-
codynamic parameters that quantify antimicrobial activity in
planktonic and bioﬁlm-growing bacteria, with P. aeruginosa as a
model organism. It is important to highlight the fact that, in
nearly all cases, these parameters are deﬁned by use of the
Calgary device or related systems. Most antibiotics show a
more than one two-fold dilution increase in the MBIC vs. MIC
or MBEC/BBC vs. MBC. Only the macrolide azithromycin,
which is not active in standard in vitro susceptibility tests,
showed bactericidal activity on bioﬁlms (Table 3). However, in
another in vitro study, using the ﬂow cell model, it was found
that, despite this good activity on bioﬁlms, resistant mutants
were readily selected, particularly hypermutable strains [58].
The resistance mechanism selected, overexpression of Mex-
CD–OprJ, was found to confer resistance to unrelated
antipseudomonal agents such as ciproﬂoxacin or cefepime,
but, in contrast, made the strains hypersusceptible to other
agents, such as aminoglycosides [58].
TABLE 2. Pharmacodynamic parameters of antimicrobial activity in planktonic and bioﬁlm-growing bacteria
Parameter Deﬁnition
MIC The lowest concentration of an antibiotic that inhibits the visible growth of a planktonic culture after overnight incubation
MBIC The lowest concentration of an antibiotic that resulted in an OD650 nm difference of ≤10% (1 log difference in growth after 6 h of incubation) of the mean
of two positive control well readings
MBC The lowest concentration of an antibiotic producing a 99.9% CFU reduction of the initial inoculum of a planktonic culture
BBC The lowest concentration of an antibiotic producing a 99.9% reduction of the CFUs recovered from a bioﬁlm culture as compared to the growth control
MBEC The lowest concentration of an antibiotic that prevents visible growth in the recovery medium used to collect bioﬁlm cells
BPC Same as the MBIC, but bacterial inoculation and antibiotic exposure occur simultaneously
BBC, bioﬁlm bactericidal concentration; BPC, bioﬁlm-prevention concentration; MBC, minimal bactericidal concentration; MBEC, minimal bioﬁlm-eradication concentration;
MBIC, minimal bioﬁlm inhibitory concentration; OD, optical density.
TABLE 3. Comparison of planktonic and bioﬁlm growth pharmacodynamic parameters of antimicrobial activity described for
Pseudomonas aeruginosa
Antibiotic MIC (mg/L) MBIC (mg/L) MBC (mg/L) MBEC (mg/L) BBC (mg/L) BPC (mg/L) Bioﬁlm model
AZT 4a >128a 8 >1024b – – Calgary device
CAZ 2a/1c/2d 128a/128d 2c/4d >1024b 16c/1024d 16d Calgary device
MER ≤1a/0.5c 4a 1c – 8c – Calgary device
IMP 2d/1e 64d/32e 4d/4e 1024e/>1024b 256d 32d Calgary device
CIP 0.5a/0.125c/1d 1a/1d 0.25c/1d 4b 2c/64d 1d Calgary device
TOB 2a/2d 4a/8d 2d 2b 64d 4d Calgary device
COL 2d/2e 16d/16e 1d/8e 128e 64d 2d Calgary device
AZM 128f/128d 2a/16d >128d – 512d 8d Calgary device
CXA-101 0.5c – 0.5c – 0.5c – Calgary device
AZM, azithromycin; AZT, aztreonam; BBC, bioﬁlm bactericidal concentration; BPC, bioﬁlm-prevention concentration; CAZ, ceftazidime; CIP, ciproﬂoxacin; COL, colistin; IMP,
imipenem; MBC, minimal bactericidal concentration; MBEC, minimal bioﬁlm-eradication concentration; MBIC, minimal bioﬁlm inhibitory concentration; MER, meropenem; TOB,
tobramycin.
aObtained from [57]. Median values of a clinical collection.
bObtained from [64]. Pseudomonas aeruginosa ATCC 27853 values.
cObtained from [88]. PAO1 values.
dObtained from [89]. Fifty per cent value of a clinical collection.
eObtained from [90]. PAO1 values.
fObtained from [58]. PAO1 values.
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Similarly, ciproﬂoxacin, which, as shown in Table 3, is one of
the most active antibiotics on bioﬁlms (MIC same as MBIC
[89]), led to the selection and ampliﬁcation of resistant
mutants in a ﬂow cell PK/PD model of P. aeruginosa bioﬁlm
treatment. In this model, a concentration of 2 mg/L ciproﬂox-
acin, which correlated with the mutant-prevention concentra-
tion and provided an area under the curve/MIC ratio of 384,
which should predict therapeutic success, was used, but
demonstrated, nevertheless, that theoretically optimized PK/
PD parameters failed to suppress resistance development on
bioﬁlms.
The results of other studies of PK/PD models of P. aeru-
ginosa bioﬁlm treatment showed time-dependent killing for
b-lactam antibiotics and concentration-dependent or
dose-dependent killing for ciproﬂoxacin, colistin, and tobra-
mycin, which is similar to what has been shown for planktonic
growth [90–92]. However, the concentrations of antibiotics
needed were, in all cases, very much higher, even in the case of
time-dependent killing, where, on b-lactamase-overproducing
bioﬁlms, the killing pattern of ceftazidime was changed to
concentration-dependent killing for bioﬁlm cells [93]. More-
over, analysis of antimicrobial activity on bioﬁlms with the ﬂow
cell CLSM model reveals that some agents (such as ciproﬂox-
acin) are effective only against the (metabolically active) outer
layers, whereas others (such as colistin) kill only the (meta-
bolically attenuated) inner layers, providing a rational approach
for establishing combination therapy [94]. These results
indicate the complexity of the interaction of bioﬁlm mecha-
nisms with antibiotic activity, and the need for deeper in vitro
and in vivo studies before antibiotic strategies based on bioﬁlm
antimicrobial susceptibility testing can be recommended rather
than conventional ones. Indeed, bioﬁlm susceptibility testing
has not yet resulted in reliable prediction of therapeutic
success in the single clinical trial performed so far [95], and
further data from future randomized clinical trials on this topic
are therefore required to shed light on this question [62,96].
Future Directions
Alternative susceptibility tests that are useful for predicting
therapeutic success for strains involved in bioﬁlm infections
are needed in the clinical microbiology laboratory. Therefore,
an effort to implement bioﬁlm-feasible antibiotic susceptibility
testing assays [55,57,64] that supply endpoints such as the
MBIC, MBEC, BBC or BPC, making them compatible with
routine clinical microbiology laboratory practicem is required.
Nevertheless, standardization of the procedures, parameters
and breakpoints, by ofﬁcial agencies such as the CLSI or the
European Committee on Antimicrobial Susceptibility Testing,
is needed before they can be implemented in clinical micro-
biology laboratories for routine susceptibility testing. More-
over, a special effort should be made to establish the optimal
growth conditions and media in an attempt to better
reproduce the conditions in vivo. In this sense, the use of
artiﬁcial sputum medium and an anaerobic atmosphere are
among the measures thought to better mimic the in vivo
conditions [97]. Other, more complex, bioﬁlm models, such as
the ﬂow cell [60], are probably not feasible for routine testing,
but should be very useful for establishing the dynamics of
bioﬁlm populations in the presence of existing and new
antibiotics, including combinations of antibiotics, to elucidate
bioﬁlm resistance mechanisms and to determine optimal PK/
PD antibiotic parameters on bioﬁlms. In addition, more in vivo
studies and clinical trials based on bioﬁlm antimicrobial
susceptibility testing-driven therapy are needed.
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